Eliyahu Sharon Kalif - 13 Feb 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: EVP, Chief Financial Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Issuer symbol: TEVA
Transactions as of: 13 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Feb 2023, 06:20:37 UTC
Previous filing: 09 Feb 2023
Next filing: 02 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+6,629	+71%		16,005	13 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-6,629	-50%	$0.000000	6,630	13 Feb 2023	Ordinary Shares	6,629		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024.